New hope for head and neck cancer: Triple-Drug combo tested after immunotherapy fails

NCT ID NCT06725368

Recruiting now Disease control Sponsor: Centre Paul Strauss Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs (carboplatin, paclitaxel, and cetuximab) in people with advanced head and neck cancer that has returned or spread. Participants must have already tried the immunotherapy drug pembrolizumab (with or without chemotherapy) and it stopped working. The goal is to see if this new combo can shrink tumors and control the disease for as long as possible. The study will enroll 46 adults in France and track their response for 12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER

Contacts and locations

Locations

CHU de Besançon
RECRUITING

Besançon, France
Centre Hospitalier de Colmar
RECRUITING

Colmar, 68024, France
Centre Paul Strauss
RECRUITING

Strasbourg, 67033, France
Centre hospitalier Régional de Metz-Thionville
RECRUITING

Ars-Laquenexy, 57085, France
Institut de cancérologie de Lorraine
RECRUITING

Vandœuvre-lès-Nancy, 54519, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.